Real-world outcomes following third or subsequent lines of therapy : A Danish population-based study on 189 patients with relapsed/refractory large B-cell lymphomas
© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd..
Outcome data of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) beyond the second line are scarce outside of clinical trials. Novel therapies in the R/R setting have been approved based on single-arm trials, but results need to be contextualized by real-world outcomes. Medical records from 3753 Danish adults diagnosed with DLBCL were reviewed. Patients previously treated with rituximab and anthracycline-based chemotherapy who received the third or later line (3 L+) of treatment after 1 January 2015, were included. Only 189 patients with a median age of 71 years were eligible. The median time since the last line of therapy was 6 months. Patients were treated with either best supportive care (22%), platinum-based salvage therapy (13%), low-intensity chemotherapy (22%), in clinical trial (14%) or various combination treatments (32%). The 2-year OS-/PFS estimates were 25% and 12% for all patients and 49% and 17% for those treated with platinum-based salvage therapy. Age ≥70, CNS involvement, elevated LDH and ECOG ≥2 predicted poor outcomes, and patients with 0-1 of these risk factors had a 2-year OS estimate of 65%. Only a very small fraction of DLBCL patients received third-line treatment and were eligible for inclusion. Outcomes were generally poor, but better in intensively treated, fit young patients with limited disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:204 |
|---|---|
| Enthalten in: |
British journal of haematology - 204(2024), 3 vom: 30. März, Seite 839-848 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Al-Mashhadi, Ahmed Ludvigsen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 14.03.2024 Date Revised 14.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.19201 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365007560 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365007560 | ||
| 003 | DE-627 | ||
| 005 | 20240314234701.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.19201 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1328.xml |
| 035 | |a (DE-627)NLM365007560 | ||
| 035 | |a (NLM)38009548 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Al-Mashhadi, Ahmed Ludvigsen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-world outcomes following third or subsequent lines of therapy |b A Danish population-based study on 189 patients with relapsed/refractory large B-cell lymphomas |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2024 | ||
| 500 | |a Date Revised 14.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a Outcome data of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) beyond the second line are scarce outside of clinical trials. Novel therapies in the R/R setting have been approved based on single-arm trials, but results need to be contextualized by real-world outcomes. Medical records from 3753 Danish adults diagnosed with DLBCL were reviewed. Patients previously treated with rituximab and anthracycline-based chemotherapy who received the third or later line (3 L+) of treatment after 1 January 2015, were included. Only 189 patients with a median age of 71 years were eligible. The median time since the last line of therapy was 6 months. Patients were treated with either best supportive care (22%), platinum-based salvage therapy (13%), low-intensity chemotherapy (22%), in clinical trial (14%) or various combination treatments (32%). The 2-year OS-/PFS estimates were 25% and 12% for all patients and 49% and 17% for those treated with platinum-based salvage therapy. Age ≥70, CNS involvement, elevated LDH and ECOG ≥2 predicted poor outcomes, and patients with 0-1 of these risk factors had a 2-year OS estimate of 65%. Only a very small fraction of DLBCL patients received third-line treatment and were eligible for inclusion. Outcomes were generally poor, but better in intensively treated, fit young patients with limited disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a clinical research | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a lymphomas | |
| 650 | 4 | |a malignant lymphomas | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 700 | 1 | |a Jakobsen, Lasse Hjort |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Gang, Anne Ortved |e verfasserin |4 aut | |
| 700 | 1 | |a Thorsteinsson, Anne-Luise |e verfasserin |4 aut | |
| 700 | 1 | |a Rasoul, Kaziwa |e verfasserin |4 aut | |
| 700 | 1 | |a Haissman, Judith Melchior |e verfasserin |4 aut | |
| 700 | 1 | |a Tøstesen, Michael Buch |e verfasserin |4 aut | |
| 700 | 1 | |a Christoffersen, Mette Niemann |e verfasserin |4 aut | |
| 700 | 1 | |a Jelicic, Jelena |e verfasserin |4 aut | |
| 700 | 1 | |a Jørgensen, Jennifer Bøgh |e verfasserin |4 aut | |
| 700 | 1 | |a Thomsen, Troels |e verfasserin |4 aut | |
| 700 | 1 | |a Dessau-Arp, Andriette |e verfasserin |4 aut | |
| 700 | 1 | |a Andersen, Andreas P H |e verfasserin |4 aut | |
| 700 | 1 | |a Frederiksen, Mikael |e verfasserin |4 aut | |
| 700 | 1 | |a Pedersen, Per Trøllund |e verfasserin |4 aut | |
| 700 | 1 | |a Clausen, Michael Roost |e verfasserin |4 aut | |
| 700 | 1 | |a Jørgensen, Judit Meszaros |e verfasserin |4 aut | |
| 700 | 1 | |a Poulsen, Christian Bjørn |e verfasserin |4 aut | |
| 700 | 1 | |a El-Galaly, Tarec Christoffer |e verfasserin |4 aut | |
| 700 | 1 | |a Larsen, Thomas Stauffer |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 204(2024), 3 vom: 30. März, Seite 839-848 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:204 |g year:2024 |g number:3 |g day:30 |g month:03 |g pages:839-848 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.19201 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 204 |j 2024 |e 3 |b 30 |c 03 |h 839-848 | ||